Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Melanoma 9Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Glioblastoma 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Skin Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × poly ICLC × Clear all
NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
8 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡